US FDA lifts import alert on Divi’s Lab unit
New Delhi: Drug firm Divi’s Laboratories Ltd on Wednesday said the US Food and Drug Administration (FDA) has lifted import alert imposed on its unit at Visakhapatnam.
Last week, the company in a regulatory filing had said the US FDA had “closed out” a warning letter issued to the unit in Visakhapatnam following evaluation of corrective actions taken by the company at the plant. “The FDA’s website has now been updated on 14 November 2017, and the import alert 66-40 on the company’s unit-II has been removed,” the company said in a BSE filing.
The US FDA in March had issued import alert under clauses 99-32 and 66-40 and a warning letter later for the Visakhapatnam facility for non-compliance of good manufacturing practices (GMP) norms, the company had informed bourses earlier.
The company in July announced that the USFDA had moved to lift Import Alert 99-32 imposed on the unit. As per the US FDA, an import alert under 66-40 entails “detention without physical examination” of drugs from firms which have not met drug GMPs while alert under 99-32 is issued to “firms refusing FDA foreign establishment inspection”.
At 11.50am, the stock was trading 0.61% higher at Rs1,030.55 on the BSE, while the Sensex fell 0.20% to 32,875.96 points.
- Gold, silver slip on sluggish demand in Mumbai
- Will decide on bringing petrol under GST after weighing revenue impact: MP minister
- Muthoot Capital raises Rs165 crore via QIP, dilutes 12.5% stake
- Gujarat elections a fight between caste politics and Modi’s development agenda: Amit Shah
- Zimbabwe’s parliament starts impeachment process against Robert Mugabe